NCT Number: NCT00467766
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease
A unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Prince of Wales Hospital, Randwick, New South Wales, Australia
About this study
This study is a single-blind prospective randomized trial with 150 patient/caregiver pairs (50 in each country). Eligibility criteria at baseline require that the primary caregiver is the spouse of the patient; the patient must have a diagnosis of AD, be in the in mild to moderate stage of dementia, be living with the caregiver, and be willing to take Donepezil (Aricept). These participants were randomly assigned to one of two groups: in one group, the intervention consists of drug treatment for the patient plus psychosocial intervention for the caregiver; in the other group the intervention consists solely of drug treatment for the patient.
The intervention for the caregiver consists of 5 scheduled individual and family counseling sessions within 3 months of baseline, and unlimited consultations on request. Assessments were conducted every 3 months for the first year and every 6 months for a second year. There are 3 sources of data: an interview of the caregiver by an independent rater, an assessment of the patient, and a count of the amount of medication used. Thus we will be able to assess the effect of adding counseling to medication for the caregiver, for the patient, and on compliance with medication use.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Individuals diagnosed with mild to moderate stage Alzheimer's disease and their spouse caregivers
Exclusion criteria
- Severe psychological or physical illness
- Unwillingness by either spouse to participate in all aspects of the study
Treatment and study plan
Donepezil (Aricept)
DrugPrimary outcomes
-
Caregiver: Changes in depression, measured with the Beck Depression Inventory
Time frame: every 3 months for the first year, and every 6 months for the second year
-
Caregiver: Changes in social support satisfaction, measured with the Stokes Social Network Scale
Time frame: every 3 months for the first year, and every 6 months for the second year
-
Patient: Changes in cognition measured by ADAS-cog
Time frame: every 3 months for the first year, and every 6 months for the second year
-
Patient: Changes in abilities with activities of daily living measured by ADCS-ADL
Time frame: every 3 months for the first year, and every 6 months for the second year
Secondary outcomes
-
Caregiver: Changes in reactions to patient behavior, physical health, family conflict and sense of mastery
Time frame: every 3 months for the first year, and every 6 months for the second year
-
Patient: Time to nursing home placement
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Important dates
- Study start
- 1999
- Study completion
- 2003
- First posted
- May 1, 2007
- Registry last updated
- May 7, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Powerful Tools for Caregivers of Dementia Patients
NCT02697721
Alzheimer Disease, Behavior
Tallahassee, Florida, United States
View Trial DetailsDeprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
NCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsImpact of COVID-19 Vaccines on Cerebrovascular Health
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsCommunity-based Brain Health Program to Address Dementia Risk
NCT05529706
Alzheimer Disease, Brain Diseases
San Francisco, California, United States
View Trial Details